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Abstract: Background: Cannabis use can increase the risk of psychosis, and the acute administration
of its key psychoactive ingredient, delta-9-tetrahydrocannabinol (∆9-THC), can induce transient
psychotomimetic symptoms. Methods: A double-blind, randomized, placebo-controlled crossover
design was used to investigate the symptomatic effects of acute intravenous administration of ∆9-THC
(1.19 mg/2 mL) in 16 healthy participants (seven males) with modest previous cannabis exposure.
Results: In the 20 min following acute ∆9-THC administration, symptomatic effects of at least mild
severity were present in 94% of the cohort, with moderate to severe symptoms having a much lower
prevalence (19%). Nearly one-third (31%) of the volunteers were still experiencing protracted mild
symptomatic effects 2.5 h after exposure to ∆9-THC. Compared to the ∆9-THC challenge, most of
the study participants did not experience any symptomatic effects following placebo administration
(62%). Acute physical reactions were 2.5 times more frequent after ∆9-THC (31%) than placebo
(12%). Male and female participants differed in terms of acute ∆9-THC effects, with some negative
symptoms occurring more frequently in female (56% to 89%) than male participants (0% to 29%), and
acute physical reactions occurring exclusively in the female gender (56%). Conclusions: These results
have implications for future research, also in light of cannabis being the most widely used illicit drug.
Keywords: delta-9-tetrahydrocannabinol; placebo; cannabis-associated psychosis; schizophrenia
1. Introduction
Psychosis is a severe mental disorder resulting from a complex interplay between genetic and
environmental determinants leading to a disruption of central nervous system function [1]. In order
to better understand its pathophysiological mechanisms, different models of psychosis have been
proposed [2]. Over the last two decades, there has been growing interest in the drug-induced model of
psychosis, due to the potential of several pharmacological agents to elicit psychotomimetic symptoms
that resemble those observed in psychosis patients [3]. In particular, in-human models of psychosis
have become available involving the acute administration of dopaminergic [4], serotoninergic [5],
glutamatergic [6], and cannabinoid compounds [7,8]. Compared to animal models, which have been
implicated as not adequately modeling the complexity of the disorder [9], the transient symptoms
induced by acute challenge with psychotomimetic drugs in healthy individuals are of interest, as they
may share pathophysiological mechanisms with the full-blown disorder.
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The administration of cannabis’ key psychoactive ingredient delta-9-tetrahydrocannabinol
(∆9-THC) has been shown to induce transient psychosis-like symptoms in otherwise healthy
individuals [10–13]. The association between cannabinoids and psychosis is further supported
by several lines of research: (i) the evidence for a higher risk of psychosis in cannabis users [14–16],
especially against a specific genetic background [17,18]; (ii) the evidence that cannabis use can
exacerbate psychotic symptoms and cause relapse in patients with schizophrenia [19–23]; and (iii) the
evidence that the endocannabinoid system might be disrupted in patients with schizophrenia both
in the context of cannabis use and in its absence [24,25], as well as involved in modulating cognitive
function in healthy individuals [26–28].
Although clinical research is needed to further understand psychosis in cannabis users, limited
evidence from anecdotal studies has been published on the nature of the transient clinical manifestations
of acute cannabis intoxication in healthy individuals [29–31]. In many respects, experimental studies
examining the nature of the psychotomimetic effects of ∆9-THC may arguably be a priority because
they can inform further studies of cannabis-associated psychosis, including aetiology, course, prognosis,
and treatment. Previous studies that have assessed the acute psychotomimetic effects of ∆9-THC
have reported them as summary measure using the PANSS (Positive and Negative Syndrome
Scale) [11,12,32–36], BPRS (Brief Psychiatric Rating Scale) [37], SSPS (State Social Paranoia Scale) [35],
or self-report questionnaires [12,32,34]. A limited range of other effects has also been investigated
using self-report questionnaires and visual analogue measures, including dissociation [12], affect and
mood [11,12,32,34–37], sedation and intoxication [11,12,36,37], and anxiety and panic [11,12,36].
Also, evidence indicates that frequent cannabis users have a more blunted response to the
acute psychotomimetic effects of ∆9-THC compared to a group of healthy controls, suggesting the
potential development of tolerance [38,39]. Thus, studies conducted among frequent users may
have limited usefulness in informing on the nature of the symptoms acutely induced by cannabis in
healthy individuals.
Employing a placebo-controlled acute pharmacological challenge design, the aim of this study was
to investigate the symptomatic effects of acute ∆9-THC administration under controlled experimental
conditions in a group of healthy individuals with modest previous cannabis use.
2. Materials and Methods
This study employed a double-blind, randomized, placebo-controlled, repeated-measures,
within-subject design, with a counterbalanced order of drug administration, using an established
protocol [13,40]. Sixteen healthy participants (seven males) were assessed on two different occasions
separated by at least a two-week interval, with each session preceded by intravenous administration of
∆9-THC (1.19 mg/ 2 mL) or placebo. All the subjects underwent structural Magnetic Resonance Imaging
(MRI), functional MRI (fMRI) and proton magnetic resonance spectroscopy (1H-MRS) scanning in
both sessions. The present report focuses on the psychopathological assessment.
2.1. Experimental Procedure
Prior to each study visit, participants were advised to get at least six to eight hours sleep overnight
and to refrain from smoking for four hours, taking caffeine for 12 h, and consuming alcohol for 24 h.
Also, subjects had been abstinent from cannabis for at least six months before the first study visit, and
were advised to abstain from using any substance throughout the duration of the study. On arrival at
the study center in the morning, participants had a light standardized breakfast after an overnight
fast. All the subjects had a negative urinary drug screen for amphetamines, benzodiazepines, cocaine,
opiates, and ∆9-THC, and were tested on each study day using immunometric assay kits. All the
female participants had a negative pregnancy test; also, all of them were consistently using a reliable
contraceptive method, apart from a single subject who underwent both study visits in the first week
of the menstrual cycle. After a physical examination performed by a medical doctor, an indwelling
intravenous line in the non-dominant arm was placed by a trained nurse. This cannula was used
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for the intravenous administration of ∆9-THC (1.19 mg/ 2 mL, ≥99% pure; THC-Pharm, Frankfurt,
Germany, http://biochem.thc-pharm.de; pharmaceutical formulation at the Barts Health NHS Trust
pharmacy according to previous work [41]) or placebo as well as blood collection a different time points
before and after drug challenge. A dose of 1.19 mg was used, as previous work has suggested that
an intravenous dose range between 0.015–0.03 mg/kg is consistently associated with an induction of
psychotomimetic symptoms [42]. Heart rate and blood pressure were monitored via a digital recorder
and an automated arm cuff for the entire duration of the study.
2.2. Subjects
Sixteen healthy, English-speaking, right-handed individuals participated in this study.
Demographic information such as age, ethnicity, and level of education was recorded. All the
subjects gave written, informed consent, and completed all of the components of the study. Personal or
family history of psychiatric illness in first-degree relatives represented an exclusion criterion. None of
the subjects included in the study had used more than 21 units/week of alcohol on a regular basis. Only
three subjects had a regular smoking habit (two of them smoking <10 cigarettes/day and one smoking
two cigarettes/week), six had smoked occasionally/experimentally, and seven had never smoked.
Apart from three subjects who had a single experimental use of 3,4-Methylenedioxymethamphetamine
(MDMA), all the remaining participants had never used any other substance. Regarding previous
lifetime cannabis exposure, nine subjects had used cannabis ≤5 times, three subjects ≤10 times, two
subjects ≤20 times, one subject 20 times, and one subject 60 times.
2.3. Psychopathological Assessment
All the participants were interviewed by a psychiatrist with a specific expertise in Diagnostic
and Statistical Manual of Mental Disorders, 5th edition (DSM-5) schizophrenia and other psychotic
disorders as well as substance use disorders [43], using the Structured Clinical Interview for DSM-5
(SCID-5) as a guide for the assessment of the psychotic spectrum [44]. Assessments were carried out
immediately before and at 20 min and 2.5 h after drug administration, and clinically discussed with a
senior psychiatrist at the end of each study visit. Psychopathological ratings were recorded using the
Positive and Negative Syndrome Scale [45] (PANSS), which is a well-established scale that is used for
measuring the symptom severity of individuals with psychosis. Verbatim quotations from participants
were also recorded, as research evidence indicates that the inclusion of excerpts from transcripts might
help clarify links between data, interpretation, and conclusion [46]. Participants were contacted the
day after each study visit for a health check as part of the study standard operating procedure (SOP).
Putative symptoms lasting longer than expected or occurring after the end of the study visit were
also recorded.
2.4. Ethics Approval
The study was approved by the Joint South London and Maudsley (SLaM) and Institute of
Psychiatry, Psychology & Neuroscience (IoPPN) National Health Service Research Ethics Committee
(PNM/13/14-38), and the investigators had a license to use ∆9-THC for research purposes.
3. Results
3.1. Demographic Information
Study participants had a mean age of 24.44 (standard deviation, SD: 4.29) years. All except three
(with self-described mixed ethnic origin) of the volunteers were white Europeans. They had 16.94 ±
2.84 years (mean, M ± SD) of education.
The effects of ∆9-THC administration on blood pressure and heart rate and related statistics as
well as ∆9-THC plasma levels have been previously reported [40].
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3.2. Prevalence and Severity of Symptoms: Results at a Glance
3.2.1. Following Acute ∆9-THC Administration
Apart from one participant with minimal and questionable symptoms, who did not score more
than two on any PANSS item, the entire study cohort reported at least mild and clearly detectable
symptomatic effects (94%; ≥3 on at least one PANSS item) within 20 min following acute challenge with
∆9-THC. More severe symptomatic effects were experienced by a smaller proportion of participants,
with 10 volunteers reporting at least moderate symptoms (62%; ≥4 on at least one PANSS item) and
three of them reporting moderate to severe symptoms (19%; ≥5 on at least one PANSS item). Acute
physical reactions, including effects on movement, blood pressure, heart rate, skin vascularity, and
vagal response, occurred on five occasions (31%).
Two hours and 30 minutes after the intravenous administration of ∆9-THC, five (31%) and three
(19%) participants were still experiencing mild (= 3 on at least one PANSS item) and minimal (= 2
on at least one PANSS item) symptoms, respectively. In contrast, by this time, no physical reaction
was evident. Upon telephone follow-up, six participants (37%) reported long-lasting effects of the
drug, which faded away by the end of the study day or the subsequent morning. These symptoms
were mainly included fatigue and food craving. In one case, these effects included psychosis-related
symptoms such as suspiciousness, hostility, tension, and poor impulse control (6%).
3.2.2. Following Placebo Administration
Differently from the ∆9-THC condition, most of the study participants did not experience any
symptomatic effects following placebo administration (n = 10; 62%). Three volunteers (19%) reported
minimal and questionable symptoms (= 2 on at least one PANSS item) and, interestingly, only three
subjects (19%) had detectable symptoms of mild severity (= 3 on at least one PANSS item). Acute
physical reactions, including effects on heart rate and skin vascularity, were present in two occasions
(12%), occurring at a lower rate compared to the ∆9-THC condition.
Two hours and 30 minutes after the intravenous administration of placebo, only one participant
(6%) was experiencing minimal and questionable psychotomimetic symptoms (= 2 on at least one
PANSS item). Also, similarly to the ∆9-THC condition, no physical reaction was evident at that time
point. Finally, differently from the ∆9-THC condition, only one participant (6%) reported long-lasting
effects at the telephone follow-up after placebo administration, which faded away by the end of the
day. However, these effects included psychosis-related symptoms such as suspiciousness, which was
totally overlapping with the frequency of long-lasting psychosis-related symptoms following acute
challenge with ∆9-THC (6%).
3.3. Symptoms Description
3.3.1. Psychosis-Related Positive Symptoms and Disorganization
The effects of ∆9-THC administration on the PANSS positive symptom subscale and related
statistics have been previously reported [40].
Conceptual disorganization was the most frequently observed symptom in the ~20 min following
the acute administration of ∆9-THC, with all the participants reporting such symptoms in a minimal to
severe form (2 ≤ PANSS-related item ≤ 6). Further frequent symptoms (≥2 on PANSS-related item)
included hallucinatory behavior (62%), excitement (62%), and suspiciousness/persecution (56%). A
lower percentage of participants also reported symptoms of grandiosity (25%), hostility (19%), and
delusions (19%).
Some symptoms were still detectable 2.5 h after the injection (≥2 on PANSS-related item), even if
in a more attenuated form, with conceptual disorganization being the most frequent symptom (37%),
followed by hallucinatory behavior (6%) and excitement (6%). Volunteers showing a more severe
conceptual disorganization immediately after the intravenous administration of ∆9-THC were more
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likely to still experience such symptom 2.5 h after the injection, with five out of nine participants
experiencing moderate to severe conceptual disorganization (4 ≤ PANSS-related item ≤ 6) versus one
out of seven participants with minimal to mild conceptual disorganization (≤3 on PANSS-related item).
In the ~20 min following the acute administration of placebo, positive symptoms were reported by
four participants (≥2 on PANSS-related item) and only two of them had clearly detectable symptoms
(mild severity, ≥3 on PANSS-related item; 12%), which was a percentage that was 7.5 times smaller
than that observed in participants under the influence of ∆9-THC. In both cases, these symptoms were
within the conceptual disorganization domain. Also, only one participant was still experiencing a
disorganized process of thinking 2.5 h after the injection of placebo.
Overall, ∆9-THC-induced excitement and grandiosity were more frequent in male (86% and 43%
respectively) than female participants (44% and 11% respectively). Instead, hostility was observable
only in a percentage of female participants (33%) (Table 1).
3.3.2. Psychosis-Related Negative Symptoms
The effects of ∆9-THC administration on the PANSS negative symptom subscale and related
statistics have been previously reported [40].
A lack of spontaneity and reduced flow of conversation was the most frequently observed
symptom in the ~20 min following the acute administration of ∆9-THC, with 13 participants reporting
such symptoms in a minimal to moderately severe form (2 ≤ PANSS-related item ≤ 5; 81%). Further
frequent symptoms (≥2 on PANSS-related item) included stereotyped thinking (69%), blunted affect
(62%), poor rapport (62%), and difficulty in abstract thinking (50%). A lower percentage of participants
also reported emotional (44%) and social withdrawal (31%). In only three participants (19%), some
symptoms were still detectable 2.5 h after the injection, even if in a more attenuated form (lack of
spontaneity and reduced flow of conversation, 12%; blunted affect, 6%; difficulty in abstract thinking,
6%; stereotyped thinking, 6%).
In the ~20 min following the acute administration of placebo, negative symptoms were detectable
only in two participants (mild severity, = 3 on PANSS-related item, 12%), which was a percentage that
was 7.5 times smaller than that observed in participants under the influence of ∆9-THC. In these cases,
symptoms included the poor rapport (6%) and/or the lack of spontaneity (12%) domains. Also, only
one participant was still experiencing a lack of spontaneity and reduced flow of conversation 2.5 h
after the injection of placebo.
Overall, ∆9-THC-induced poor rapport, emotional withdrawal, and social withdrawal were more
frequent in female participants (56% to 89%) than male participants (0% to 29%) (Table 2).
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Table 1. Psychosis-related positive symptoms and disorganization.
Study Participant Drug Delusions Conceptual Disorganization HallucinatoryBehavior Excitement Grandiosity Suspiciousness/Persecution Hostility
male 1 ∆9-THC × mild × minimal × mild ×
male 2 ∆9-THC × textsurd mild × textsurd mild textsurd minimal × ×
male 3 ∆9-THC × textsurd severe textsurd mild textsurd moderate textsurd moderate textsurd mild ×
male 4 ∆9-THC × textsurd minimal × textsurd minimal × × ×
male 5 ∆9-THC × textsurd moderate textsurd mild × × textsurd minimal ×
male 6 ∆9-THC textsurd mild textsurd moderate textsurd mild textsurd moderate textsurd moderate × ×
male 7 ∆9-THC × textsurd moderate textsurd mild textsurd mild × textsurd minimal ×
female 1 ∆9-THC × textsurd mild × × × × textsurd mild
female 2 ∆9-THC × textsurd mild textsurd mild × × × ×
female 3 ∆9-THC × textsurd mild × textsurd mild × × ×
female 4 ∆9-THC × textsurd moderate textsurd minimal textsurd mild × textsurd mild textsurd mild
female 5 ∆9-THC × textsurd mild textsurd mild textsurd mild × textsurd mild ×
female 6 ∆9-THC × textsurd moderate textsurd mild textsurd minimal × × ×
female 7 ∆9-THC × textsurd moderate × × × textsurd minimal ×
female 8 ∆9-THC textsurd moderate textsurd moderate/severe textsurd severe × textsurd moderate textsurd minimal ×
female 9 ∆9-THC textsurd minimal textsurd moderate textsurd moderate × × textsurd moderate textsurd mild
male 1 placebo × × × × × × ×
male 2 placebo × × × × × × ×
male 3 placebo × × × textsurd minimal × × ×
male 4 placebo × × × × × × ×
male 5 placebo × textsurd mild × × × × ×
male 6 placebo × × × × × × ×
male 7 placebo × textsurd mild textsurd minimal × × × ×
female 1 placebo × × × × × × ×
female 2 placebo × × × × × × ×
female 3 placebo × × × minimal × × ×
female 4 placebo × × × × × × ×
female 5 placebo × × × × × × ×
female 6 placebo × × × × × × ×
female 7 placebo × × × × × × ×
female 8 placebo × × × × × × ×
female 9 placebo × × × × × × ×
∆9-THC, (−)-trans-∆9-tetrahydrocannabinol; symptoms highlighted in bold were still observable 2.5 h after the injection.
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Table 2. Psychosis-related negative symptoms.
Study Participant Drug Blunted Affect Emotional Withdrawal Poor Rapport Social Withdrawal Difficulty inAbstract Thinking
Lack of Spontaneity and
Flow of Conversation
Stereotyped
Thinking
male 1 ∆9-THC textsurd minimal × × × × textsurd mild textsurdminimal
male 2 ∆9-THC textsurd mild × × × textsurd mild textsurd mild textsurdminimal
male 3 ∆9-THC × × textsurd mild × textsurd moderate textsurd minimal textsurd mild
male 4 ∆9-THC × × × × × × ×
male 5 ∆9-THC × × × × × textsurd moderate textsurdminimal
male 6 ∆9-THC × × × × textsurd mild × textsurdminimal
male 7 ∆9-THC textsurd mild × textsurd moderate × × textsurd moderate textsurd mild
female 1 ∆9-THC textsurd minimal textsurd mild textsurd mild textsurd mild textsurd mild textsurd mild textsurd mild
female 2 ∆9-THC × × × × × textsurd mild ×
female 3 ∆9-THC × textsurd mild textsurd minimal × × textsurd mild ×
female 4 ∆9-THC textsurd mild textsurd mild textsurd mild × textsurd moderate textsurd moderate textsurd mild
female 5 ∆9-THC textsurd mild × textsurd mild textsurd mild textsurd moderate textsurd mild textsurd mild
female 6 ∆9-THC textsurd moderate textsurd mild textsurd mild textsurd mild × textsurd moderate ×
female 7 ∆9-THC textsurd mild textsurd moderate textsurd mild textsurd mild textsurd moderate/severe textsurd mild ×
female 8 ∆9-THC textsurdmoderate/severe textsurd moderate/severe textsurd severe textsurd moderate textsurd moderate textsurd moderate/severe
textsurd
moderate
female 9 ∆9-THC textsurd mild textsurd minimal textsurd mild × × × textsurdminimal
male 1 placebo × × × × × × ×
male 2 placebo × × × × × × ×
male 3 placebo × × × × × × ×
male 4 placebo × × × × × × ×
male 5 placebo × × × × × textsurd mild ×
male 6 placebo × × × × × × ×
male 7 placebo × × textsurd mild × × textsurd mild ×
female 1 placebo × × × × × × ×
female 2 placebo × × × × × × ×
female 3 placebo × × × × × × ×
female 4 placebo × × × × × × ×
female 5 placebo × × × × × × ×
female 6 placebo × × × × × × ×
female 7 placebo × × × × × × ×
female 8 placebo × × × × × × ×
female 9 placebo × × × × × × ×
∆9-THC, (−)-trans-∆9-tetrahydrocannabinol; symptoms highlighted in bold were still observable 2.5 h after the injection.
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3.3.3. Psychosis-Related General Psychopathology
The effects of ∆9-THC administration on the PANSS general psychopathology subscale and related
statistics have been previously reported [40].
Poor attention was the most frequently observed symptom in the ~20 min following the acute
administration of ∆9-THC, with 14 participants reporting such symptoms in a mild to moderate form
(3 ≤ PANSS-related item ≤ 4; 87%). Most of the participants also experienced a disturbance of volition
(75%), disorientation (69%), and poor impulse control (62%). Further frequent symptoms (≥ 2 on
PANSS-related item) included somatic concern (50%), preoccupation (50%), motor retardation (50%),
mannerisms and posturing (50%), unusual thought content (50%), tension (44%), and active social
avoidance (44%). A lower percentage of participants also reported a lack of judgment and insight
(37%), symptoms of anxiety and depression (31%), uncooperativeness (31%), and feelings of guilt
(12%). One participant reported feeling less depressed after the acute challenge with ∆9-THC.
Some symptoms were still detectable 2.5 h after the injection (≥2 on PANSS-related item), even if
in a more attenuated form, with poor attention and disorientation being the most frequent symptom
(31%), followed by motor retardation (12%), somatic concern (6%), preoccupation (6%), anxiety (6%),
tension (6%), and uncooperativeness (6%).
In the ~20 min following the acute administration of placebo, general psychopathological
symptoms were observable in six participants (≥2 on PANSS-related item) and only three of them had
clearly detectable symptoms (mild severity, = 3 on PANSS-related item; 19%), which was a percentage
that was five times smaller than that observed in participants under the influence of ∆9-THC. In these
cases, symptoms included poor attention (12%), somatic concern and preoccupation (6%), tension
(6%), disorientation (6%), disturbance of volition (6%), and poor impulse control (6%). Also, only
one participant was still experiencing a disturbance of volition 2.5 h after the injection of placebo.
Male and female participants were similar in terms of the prevalence of ∆9-THC-induced general
psychopathology (Table 3).
3.4. Subjects’ Quotes
Table 4 reports the most relevant symptoms experienced by the participants from a narrative
perspective. The quality of symptoms showed similarity to the psychotic symptoms reported
by schizophrenia patients. When under the acute effect of ∆9-THC, individuals reported both
positive and negative symptoms. The most relevant positive symptoms induced by ∆9-THC
included suspiciousness, paranoid and grandiose ideas/delusions, conceptual disorganization, and
perceptual alterations. Negative symptoms included reduced rapport, a lack of spontaneity, emotional
withdrawal, and concrete thinking. The administration of∆9-THC also induced altered body perception,
depersonalization/derealization, slowing of time, euphoria, and anxiety.
3.5. Additional Symptoms
Additional symptoms not necessarily related to psychosis also occurred during the trial.
In particular, five female participants (56%) had an acute physical reaction to the∆9-THC administration,
including generalized tremors, vagal reaction, paleness, orthostatic hypotension, sick feeling, flushing,
and symptoms of fainting. In contrast, no male participant experienced any physical reaction after
the drug challenge. Less intense physical reactions also occurred during the placebo session in two
occasions (Table 5).
After the intravenous administration of∆9-THC, eight volunteers (50%) showed difficulty in motor
coordination and indecisiveness with different levels of severity (Table 5; the most severe occurrence is
shown in Figure 1). A participant had a protracted posture alteration. Also, two participants showed
over-inclusive thinking and protracted internal absorption, respectively (Table 5).
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Table 3. Psychosis-related general psychopathology.
Study
Participant Drug
Somatic
Concern Anxiety Guilt Feelings Tension
Mannerism
and Posturing Depression Motor Retardation Uncooperative
Unusual
Thought
Content
Disorientation Poor Attention
Lack of
Judgment &
Insight
Disturbance of
Volition
Poor Impulse
Control Preoccupation
Active Social
Avoidance
male 1 ∆9-THC textsurdminimal × × × textsurdminimal ↓ × × × textsurdminimal textsurdmild × × textsurdminimal textsurdmild ×
male 2 ∆9-THC × × × × textsurdminimal × textsurdmild × × textsurdmild textsurdmild × textsurdmild × textsurdmild textsurdmild
male 3 ∆9-THC textsurdmild × textsurd mild × × textsurdminimal × × textsurdmild textsurdmild textsurdmoderate × textsurdmoderate textsurdmild textsurdmild textsurdminimal
male 4 ∆9-THC × × × × × × × × × × × × × textsurdminimal × ×
male 5 ∆9-THC textsurdmild textsurdmild × textsurdmild × textsurdmild × × × textsurdmild textsurdmoderate × textsurdmild textsurdmild textsurdmild ×
male 6 ∆9-THC × × × × textsurdmoderate × × × textsurdmild textsurdminimal textsurdmild textsurdmild textsurdmild textsurdmild × ×
male 7 ∆9-THC textsurdmild textsurdminimal × textsurdminimal × × textsurdmild textsurdminimal textsurdminimal textsurdmild textsurdmoderate textsurdmild textsurdmoderate × × ×
female 1 ∆9-THC × × textsurdminimal textsurdminimal × textsurdminimal textsurdmild textsurdmild textsurdminimal textsurdminimal textsurdmild × textsurdmild textsurdmild × textsurdminimal
female 2 ∆9-THC × × × × × × textsurdminimal × × × × × × textsurdminimal × ×
female 3 ∆9-THC textsurdmild × × textsurdmild × × × × × × textsurdmild × textsurdmild × textsurdmild ×
female 4 ∆9-THC × × × × textsurdminimal × textsurdmild textsurdminimal textsurdmild textsurdmild textsurdmoderate textsurdmild textsurdmild textsurdmild × textsurdminimal
female 5 ∆9-THC textsurdmild textsurdmoderate × textsurdmild textsurdminimal textsurdminimal × × textsurdmild textsurdmild textsurdmild × textsurdmild × textsurdmoderate ×
female 6 ∆9-THC × × × × textsurdmild textsurdmild textsurdmoderate × × textsurdmild textsurdmoderate textsurdminimal textsurdmild × × textsurdmild
female 7 ∆9-THC textsurdmild textsurdmild × textsurdmild × × textsurdmild × × × textsurdmild × textsurdmild textsurdminimal textsurdminimal textsurdmild
female 8 ∆9-THC textsurdmild textsurdmild × textsurdmild textsurdmild × textsurdmod./severe textsurdminimal textsurdmoderate textsurdmild textsurdmoderate textsurdmoderate textsurdmoderate × textsurdmod./severe textsurdmild
female 9 ∆9-THC × × × × textsurdminimal × × textsurdmild textsurdmild × textsurdmoderate textsurdmild × textsurdminimal × ×
male 1 placebo × × × × × × × × × × × × × × × ×
male 2 placebo × × × × × × × × × × × × × × × ×
male 3 placebo × textsurdminimal × × × × × × × textsurdminimal × × × × × ×
male 4 placebo × × × × × × × × × × × × × × × ×
male 5 placebo × × × × × × × × × textsurdmild textsurdmild × × textsurdmild × ×
male 6 placebo × textsurdminimal × textsurdminimal × × × × × × × × × × × ×
male 7 placebo × × × × × × × × × × textsurdmild × textsurdmild × × ×
female 1 placebo textsurdmild textsurdminimal × textsurdmild textsurdminimal × × × × × × × × × textsurdmild ×
female 2 placebo × × × × × × × × × × × × × × × ×
female 3 placebo × × × × × × × × × × textsurdminimal × × × × ×
female 4 placebo × × × × × × × × × × × × × × × ×
female 5 placebo × × × × × × × × × × × × × × × ×
female 6 placebo × × × × × × × × × × × × × × × ×
female 7 placebo × × × × × × × × × × × × × × × ×
female 8 placebo × × × × × × × × × × × × × × × ×
female 9 placebo × × × × × × × × × × × × × × × ×
∆9-THC, (−)-trans-∆9-tetrahydrocannabinol; symptoms highlighted in bold were still observable 2.5 h after the injection.
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Table 4. Subjects’ quotes.
Study Participant ∆9-THC Symptom
male 1 ‘I was so stressed, irritable, and prone to anger that I started an argument with my partner theafternoon after the study’ Hostility, irritability, mood lability
male 2 ‘I feel I am all over the place and can’t stop laughing, thinking you will expose me, I will saysomething stupid or strange’
Conceptual disorganization, thought disorder,
loosening of associations, excitement
male 3 ‘I can’t follow my thoughts, I am not able to think’ Conceptual disorganization, racing thoughts
male 3 ‘I can understand things better and look for details, I am superior to others’ Grandiosity
male 3 ‘I might have done something wrong, not willing to say’ Feelings of guilt
male 3 ‘I am thinking about death and cemeteries’ Unusual thought content
male 6 ‘The injection changed me into someone with increased abilities’ Grandiosity
male 7 ‘I am feeling quite confused and disoriented, like time is passing slower and the space isdifferent, like from a camera zoom’ Conceptual disorganization, disorientation
female 1 ‘I am not interested and I am not willing to talk, I don’t care, I want just to go... I feel down,under the weather; maybe I am depressed’ Negative symptoms, depression
female 4 ‘What have you done to me? I understand, you want to make me paranoid with brainwashingquestions...’ Suspiciousness/paranoia with loss of insight
female 4 ‘What an apple and a ball have in common...You can eat the apple, but not the ball’ Difficulty in abstract thinking
female 5 ‘I thought you were going to attack me, people are entering the room to check on me’ Suspiciousness/paranoia, ideas of reference
female 7 ‘What an apple and a ball have in common...You can put the apple in the ball’ Difficulty in abstract thinking
female 8 ‘My mind went blank, empty, with no thoughts’ Thought blocking
female 8
‘The ventilator’s noise is louder...This noise is actually rain, it’s raining inside the room, I can
see and feel it, there is a black sky with seven blue drops, I can count them, someone has
opened the ceiling to let the rain in, and put my bed closer to the ceiling...Maybe someone is
projecting a sky in front of me’
Inability to ‘filter’ out irrelevant background stimuli,
hallucinatory behavior, secondary delusions
female 9 ‘Is this real? Is this a fake interview made by a fake doctor, like a Truman show?’ Depersonalization/derealization
female 9 ‘Colors are brighter, noises louder, and I have something making a noise in the back of my head’ Hallucinatory behavior
male 3, 7; female 5, 7 ‘I think I am going to chock up...something is wrong with my body...the heart is racing’ Preoccupation/somatic concern, anxiety/tension
Study Participant Placebo Symptom
male 7 ‘I felt spaced out, a little bit paranoid and upset after a conversation with someone who had astrange facial expression’ Suspiciousness/paranoia
∆9-THC, (−)-trans-∆9-tetrahydrocannabinol.
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Table 5. Additional symptoms.
Study Participant ∆9-THC
physical reactions
female 2 generalized tremors, vagal reaction
female 3 about to faint
female 5 about to faint, paleness
female 6 about to faint, orthostatic hypotension, sick feeling
female 8 flushing
observed symptoms
males 2, 3, 6; females 1, 2, 3, 4, 8 Different handwriting, errors and corrections in filling out the questionnaires (still present at 2.5 h after the injection for males 3 and 6)
male 6 The participant kept the arm in a distinctively awkward position for 30 min
female 4 The participant committed errors when asked four times to recall words related to a memory task (night instead of black 2/4, vegetableinstead of apple 3/4, crisis instead of cries 4/4)
female 8 The participant was internally absorbed and didn’t engage at all with a cognitive task
reported long-lasting symptoms (telephone follow-up)
male 1 suspiciousness, hostility, tension, and poor impulse control until afternoon
male 1 headache, sick and weak feeling, fatigue, exhaustion, physical and mental strain until day after
male 2 tiredness, sleepiness, postprandial somnolence
male 6 disorientation and tiredness until evening
female 5 tiredness and cravings for savory foods until afternoon
female 6 tiredness, sleepiness, and hunger until the end of the day
female 9 sleepiness, thirst, and hungry
females 1 and 4 Symptoms reported during the trial were the same experienced in the past when using recreational cannabis
Study participant Placebo
physical reactions
female 1 flushing, drowsiness, stomach pain
female 6 flushing, increase in heart rate, heavy chest feeling
reported long-lasting symptoms (telephone follow-up)
male 7 suspiciousness until afternoon
∆9-THC, (−)-trans-∆9-tetrahydrocannabinol.
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4. Discussion
The purpose of this clinical investigation was to systematically assess the transient psychotic
reaction to the intravenous administration of pure ∆9-THC in healthy subjects in a controlled setting,
which was in line with the evidence that this cannabinoid represents a valid pharmacologic model for
psychosis [10–12]. Results from this study indicate: (i) detectable acute ∆9-THC-induced symptomatic
effects in over 90% of the cohort, with moderate to severe symptoms having a lower prevalence (<20%);
(ii) protracted minimal to mild ∆9-THC-induced symptomatic effects in 50% of the cohort (~2.5 h after
the exposure); (iii) acute physical reactions to ∆9-THC in about 30% of the cohort and only in female
participants; (iv) long-lasting ∆9-THC-induced physical symptoms and psychosis-related symptomatic
effects in less than 40% and 6% of the cohort, respectively; (v) detectable and mild symptomatic effects
after placebo administration in less than 20% of the cohort; (vi) protracted minimal and questionable
symptomatic effects after placebo administration in 6% of the cohort (~2.5 h after the exposure); (vii)
acute physical reactions to placebo in about 12% of the cohort and only in female participants; and
(viii) long-lasting symptomatic effects of placebo in only 6% of the cohort.
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The constellation of symptomatic effects induced by ∆9-THC resembled several dimensions
of psychotic disorders and overlapped with evidence from previous acute challenge studies with
∆9-THC [12]. However, in order to better understand the extent of its detrimental effects, this
investigation took into account the potential nonspecific effects of the drug administration, the
so-called placebo effects when they are beneficial, and nocebo effects when they are harmful [47]. Study
participants reported a number of symptoms and signs when administered placebo, indicating a nocebo
effect. Both psychological (conditioning, negative expectations) and neurobiological (cholecystokinin,
endogenous opioids, and dopamine) mechanisms might explain the nocebo effects observed in
this study [48]. When controlling for the prevalence, quality, and severity of the subjective and
objective changes occurring under placebo, the manifestation of symptomatic effects following ∆9-THC
administration remained significantly higher and of greater severity, with most of the transient
psychosis-like symptoms occurring only under ∆9-THC. Also, psychotomimetic symptoms lasted
significantly longer under ∆9-THC compared to the placebo condition. Similarly, some objective
protracted symptoms such as poor motor coordination, posture alteration, over-inclusive thinking,
and internal absorption occurred only under ∆9-THC.
Relatively longer-lasting (<24 h) self-reported effects such as tiredness, sleepiness, and increased
appetite occurred only under ∆9-THC. Acute physical reactions to the intravenous administration
of the drug were more prevalent and clinically more severe in participants under the influence of
∆9-THC than under placebo. Also, they appeared to be gender-specific, with only female participants
showing such reactions. Physical and somatic effects were not unexpected, as ∆9-THC has been shown
to acutely induce sedation and intoxication [40].
Upon comparing results from this study with previous research, several factors need to be
considered, including, but not limited to, the degree of current cannabis use (tolerance effect) and
lifetime cannabis exposure (residual effect) of the study samples, and study design. Some research
evidence indicates less prominent acute behavioral effects of ∆9-THC in current cannabis users [49],
individuals with a past history of frequent cannabis use [38], and when administering ∆9-THC
orally [50], as also recently reviewed [39]. Further evidence suggests that the development of tolerance
may be explained by the less marked effects of acute ∆9-THC administration on brain function [51,52].
Participants taking part in our intravenous ∆9-THC challenge had been abstinent from cannabis for at
least six months. Apart from one subject, the study cohort had also modest previous cannabis exposure.
Altogether, previous evidence and our findings suggest that healthy subjects with modest previous
cannabis exposure and a proper abstinent period might be more reliable to study the psychotropic
effect of ∆9-THC and its underlying mechanisms.
Only individuals with negligible use of other substances (alcohol, tobacco, and other illicit drugs)
were invited to take part in the study. Therefore, we can reasonably rule out the possibility that some
of the results observed could be attributed to the effects of other substance use. Moreover, this study
observed an interval between the two study visits of at least 14 days. This allows us to exclude the
possibility of carryover effects from the first session, in light of evidence that ∆9-THC has an elimination
half-life of 18 h to 4.3 days [53]. Furthermore, all the participants’ urine samples collected at each study
visit baseline were negative for the presence of ∆9-THC.
For the purpose of the study and due to ethical reasons, individuals with cannabis dependence
or previous negative response to cannabis were excluded from the study. While this allowed us to
examine a more homogeneous sample, this might have limited the application of the present results
to the general population. Also, caution should be used when making inferences to the general
population, as this experiment was conducted in a relatively small sample. The intravenous route
of administration was used to allow much more consistent ∆9-THC blood levels across participants
and potentially reduce inter-individual variability in drug response [12]. For instance, absorption is
slower when cannabinoids are ingested, with ∆9-THC peak concentrations that are lower and more
delayed [54], and absorption may also considerably vary between subjects [55]. Similarly, another line
of research suggests that cannabinoid levels following cannabis smoking may vary depending on how
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intensively and efficiently people smoke [56]. However, the intravenous route of administration might
have affected the generalizability of the results to the effects of recreational cannabis use. Future studies
are needed to assess in the same individuals the effects of acute cannabis challenge using different
routes of administration.
5. Conclusions
In conclusion, these results provide further evidence of the psychoactive properties of ∆9-THC
and have implications for research in this area. Acute psychosis can be secondary to cannabis use,
with some patients relapsing with a similar presentation, and a proportion developing a long-lasting
psychotic disorder [57]. More research is needed into the chronology and components of the onset
of cannabis-associated psychosis. Acute ∆9-THC challenge studies may help elucidate the nature of
psychotic symptom development in cannabis users, ultimately enhancing our understanding of the
onset, course, and outcome of cannabis-associated psychosis.
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